Home PageNews PageViaLase ViaLase Receives CE Mark for First Femtosecond Laser for the Treatment of Glaucoma, the ViaLase® Laser ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma…Arboretum_JDJuly 30, 2024
Home PageNews PageViaLase ViaLase Closes $40M Series C Financing to Advance First Femtosecond Laser for the Treatment of Glaucoma ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional…Arboretum_JDApril 1, 2024
ViaLase Completes Enrollment for the Pivotal VIA-002 Trial of the ViaLase® Laser to Treat Primary Open Angle Glaucoma News PageViaLase ViaLase Completes Enrollment for the Pivotal VIA-002 Trial of the ViaLase® Laser to Treat Primary Open Angle Glaucoma ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma…Arboretum_JDOctober 31, 2023
Vialase Announces Positive Results of First In-Human Study of Femtosecond Laser Image-Guided High-Precision Trabeculotomy (FLigHT) ViaLase Vialase Announces Positive Results of First In-Human Study of Femtosecond Laser Image-Guided High-Precision Trabeculotomy (FLigHT) ViaLase, Inc., a clinical stage medical technology company focused on addressing unmet needs in the…Arboretum_JDMarch 3, 2023
ViaLase Founder and CEO Tibor Juhasz, PhD, Receives 2022 Golden Goose Award News PageViaLase ViaLase Founder and CEO Tibor Juhasz, PhD, Receives 2022 Golden Goose Award ViaLase, Inc., announced that the company’s founder and CEO, Tibor Juhasz, Ph.D., was among five…Arboretum_JDOctober 11, 2022